Respiratory
Pulmonary Edema
14
Pipeline Programs↗
3
Active Trials↗
7
Companies Involved↗
Pulmonary Edema is an emerging landscape with 14 programs across 7 companies. The most active players are Viatris Specialty LLC, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Validus Pharmaceuticals. 6 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 11
Phase 25
Phase 3
No programs
Analysis
Trial Status
13
clinical trials
Completed6 · 46%
Recruiting2 · 15%
Terminated2 · 15%
Unknown status2 · 15%
Not yet recruiting1 · 8%
Clinical Trials
Trial Activity
13 trials
Optimized Treatment of Pulmonary Edema or Congestion
Recruiting·—·Phase 4·NCT05276219·1,104 enrolled
Sildenafil for Swimming-Induced Pulmonary Edema (SIPE) Prevention
Completed·—·Phase 2·NCT03686813·18 enrolled
Prevention and Treatment of Immersion Pulmonary Edema
Completed·—·Phase 1·NCT00815646·10 enrolled
MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)
Terminated·—·Phase 4·NCT02856698·111 enrolled
Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography
Terminated·—·Phase 4·NCT03490916·18 enrolled
High Versus Low Dose Nitroglycerin in Acute Pulmonary Edema
Unknown status·—·Phase 2/3·NCT06107465·60 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)